Biostatistics in clinical trials /
Saved in:
| Imprint: | Chichester [England] ; New York : J. Wiley, c2001. |
|---|---|
| Description: | xx, 501 p. : ill. ; 26 cm. |
| Language: | English |
| Series: | The Wiley reference series in biostatistics Wiley reference series in biostatistics. |
| Subject: | |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/4424163 |
Table of Contents:
- Adaptive and Dynamic Methods of Treatment Assignment
- Antibacterial Agent Trials
- Audit and Quality Control
- Bayesian Methods
- Benefit/Risk Assessment
- Binding or Masking
- Clinical Significance Versus Statistical Significance
- Clinical Trials, Overview
- Cluster Randomization
- Cochrane Collaboration
- Community Intervention Trials
- Compliance Assessment
- Consort
- Controlled Clinical Trials
- Cooperative Cancer Trials
- Cooperative Heart Disease Trials
- Cooperative Studies Program, US Department of Veterans Affairs
- Cost-effectiveness
- Covariate Imbalance, Adjustment for
- Crossover Designs
- Data and Safety Monitoring
- Data and Safety Monitoring Boards
- Data Management and Coordination
- Drug Approval and Regulation
- Drug Interactions
- Eligibility and Exclusion Criteria
- Equivalence Trials
- Ethics
- European Federation of Statisticians in the Pharmaceutical Industry (EFPSI)
- European Organization for Research and Treatment of Cancer (EORTC)
- Factorial Designs
- Fraud
- Group-randomization Designs
- Guidelines
- Historical Controls, Bias From
- History, Early Cancer and Heart Disease Trials
- History, Overview
- Intention-to-Treat Analysis
- International Studies of Infarct Survival (ISIS)
- Medical Ethics and Statistics
- Medical Research Council (MRC) Streptomycin Trial
- Meta-analysis
- Missing Data
- Multicenter Trials
- Multiple Endpoints
- Multiplicity
- Noncompliance, Adjustment for
- Nonrandomized Trials
- NSABP and Advances in the Treatment of Breast Cancer
- Number Needed to Treat (NNT)
- Outcome Measures
- Pharmaceutical Industry, Statistics in
- Phase I Trials
- Phase II Trials
- Physicians' Health Study
- Postmarketing Surveillance of New Drugs and Assessment of Risk
- Preclinical Treatment Evaluation
- Prevention Trials
- Protocols
- Quorom
- Randomization
- Randomized Treatment Assignment
- Salk Vaccine
- Sample Size Determination
- Screening Trials
- Sequential Methods
- Society for Clinical Trials
- Software
- Statistical Review for Medical Journals
- Statistical Review for Medical Journals, Guidelines for Authors
- Statisticians in the Pharmaceutical Industry (PSI)
- Surrogate Endpoints
- Textbooks
- Time-varying Treatment Effect
- Treatment--Covariate Interaction
- University Group Diabetes Program (UGDP)
- Vaccine Studies
